Clinical Study Results
Research Sponsor: Acerta Pharma B.V., a member of the
AstraZeneca group of companies
Drug Studied: Acalabrutinib
Study Purpose: This study was done to learn about the
safety of acalabrutinib in participants
with a type of B-cell lymphoma
Protocol Number: ACE-LY-002
Thank you
Thank you to the participants who took part in the clinical study for the study drug
acalabrutinib, also called ACP-196.
Acerta Pharma B.V., a member of the AstraZeneca group of companies,
sponsored this study and believes it is important to share the results. An
independent non-profit organization called CISCRP helped prepare this summary
of the study results for you.
If you participated in the study and have questions about the results, please
speak with the study doctor or staff at your study site.
1